The FDA has accepted chronic pain drug Zohydro for review, pharmaceutical company Zogenix announced this week.
Zohydro is an oral, extended-release formulation of various strengths of hydrocodone intended to be taken every 12 hours. If approved, it could be the first hydrocodone product to offer less frequent dosing and no risk of acetaminophen-related liver injury.
The agency aims to finish its review of the moderate-to-severe chronic pain treatment drug by March 2013.
American Academy of Pain Medicine Applauds New FDA Opioid Requirements
Pain Specialist Dr. Corey Hunter Named Medical Director of EP Global Communications
Zohydro is an oral, extended-release formulation of various strengths of hydrocodone intended to be taken every 12 hours. If approved, it could be the first hydrocodone product to offer less frequent dosing and no risk of acetaminophen-related liver injury.
The agency aims to finish its review of the moderate-to-severe chronic pain treatment drug by March 2013.
Related Articles on Pain Management:
10 Interventional Pain Management Specialists Founding Ambulatory Surgery CentersAmerican Academy of Pain Medicine Applauds New FDA Opioid Requirements
Pain Specialist Dr. Corey Hunter Named Medical Director of EP Global Communications